Entrada Therapeutics/$TRDA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Entrada Therapeutics
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
Ticker
$TRDA
Sector
Primary listing
Employees
183
Headquarters
Website
TRDA Metrics
BasicAdvanced
$220M
-
-$1.79
-0.13
-
Price and volume
Market cap
$220M
Beta
-0.13
52-week high
$21.19
52-week low
$4.93
Average daily volume
321K
Financial strength
Current ratio
18.641
Quick ratio
18.047
Long term debt to equity
12.986
Total debt to equity
14.425
Profitability
EBITDA (TTM)
-92.255
Gross margin (TTM)
-69.38%
Net profit margin (TTM)
-92.30%
Operating margin (TTM)
-121.00%
Effective tax rate (TTM)
4.62%
Revenue per employee (TTM)
$430,000
Management effectiveness
Return on assets (TTM)
-11.66%
Return on equity (TTM)
-18.12%
Valuation
Price to revenue (TTM)
3.193
Price to book
0.58
Price to tangible book (TTM)
0.58
Price to free cash flow (TTM)
-2.005
Free cash flow yield (TTM)
-49.88%
Free cash flow per share (TTM)
-3.088
Growth
Revenue change (TTM)
-66.80%
Earnings per share change (TTM)
-158.85%
3-year earnings per share growth (CAGR)
-21.17%
What the Analysts think about TRDA
Analyst ratings (Buy, Hold, Sell) for Entrada Therapeutics stock.
TRDA Financial Performance
Revenues and expenses
TRDA Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Entrada Therapeutics stock?
Entrada Therapeutics (TRDA) has a market cap of $220M as of October 16, 2025.
What is the P/E ratio for Entrada Therapeutics stock?
The price to earnings (P/E) ratio for Entrada Therapeutics (TRDA) stock is 0 as of October 16, 2025.
Does Entrada Therapeutics stock pay dividends?
No, Entrada Therapeutics (TRDA) stock does not pay dividends to its shareholders as of October 16, 2025.
When is the next Entrada Therapeutics dividend payment date?
Entrada Therapeutics (TRDA) stock does not pay dividends to its shareholders.
What is the beta indicator for Entrada Therapeutics?
Entrada Therapeutics (TRDA) has a beta rating of -0.13. This means that it has an inverse relation to market volatility.